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Abstract
Background: The human parasite Onchocerca volvulus harbours Wolbachia endosymbionts essential for worm
embryogenesis, larval development and adult survival. In this study, the development of Wolbachia-depleted
microfilariae (first stage larvae) to infective third stage larvae (L3) in the insect vector Simulium damnosum was
analysed.
Methods: Infected volunteers in Cameroon were randomly and blindly allocated into doxycycline (200 mg/day for
6 weeks) or placebo treatment groups. After treatment, blackflies were allowed to take a blood meal on the
volunteers, captured and dissected for larval counting and DNA extraction for quantitative real-time PCR analysis.
Results: PCR results showed a clear reduction in Wolbachia DNA after doxycycline treatment in microfilariae from
human skin biopsies with > 50% reduction at one month post-treatment, eventually reaching a reduction of >
80%. Larval stages recovered from the insect vector had similar levels of reduction of endosymbiotic bacteria.
Larval recoveries were analysed longitudinally after treatment to follow the kinetics of larval development.
Beginning at three months post-treatment, significantly fewer L3 were seen in the blackflies that had fed on
doxycycline treated volunteers. Concomitant with this, the proportion of second stage larvae (L2) was significantly
increased in this group.
Conclusions: Doxycycline treatment and the resulting decline of Wolbachia endobacteria from the microfilaria
resulted in retarded development of larvae in the insect vector. Thus, anti-wolbachial treatment could have an
additive effect for interrupting transmission by reducing the number of L3 that can be transmitted by blackflies.
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Background
Onchocerciasis, caused by Onchocerca volvulus,i se n d e -
mic in many sub-Saharan countries with further foci in
Latin America and Yemen [1,2]. The number of infec-
tions is estimated to be ~ 37 million [3,4]. The chronic
nature and morbidity of onchocerciasis is associated
with microfilariae (first stage larvae; Mf) that migrate
through the skin and the eye. When the Mf die, the
immune response to the dead larvae can result in der-
matitis, skin atrophy and inflammation in the eyes. The
latter can progress into reduced vision and blindness.
Vector control and mass treatment with ivermectin, a
strong microfilaricidal drug which can produce tempor-
ary sterility [5], have been successfully used to regionally
reduce the burden of parasite infection. Due to the
resumption of fertility after interruption of ivermectin
treatment, the drug has to be administered for many
years. Studies in Ghana have identified O. volvulus
populations that are less responsive to ivermectin [6-10],
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before ivermectin resistance may develop and spread.
Ideally a new drug would have macrofilaricidal and/or
permanent sterilising activity.
In recent years, key drug trials have been performed
with a new chemotherapeutical approach to anti-filarial
therapy, the targeting of the essential Wolbachia endo-
bacteria present in many filariae with the antibiotic dox-
ycycline. This approach has resulted in long-term
sterilisation of adult female worms in onchocerciasis
[11-14]. More importantly, anti-wolbachial therapy also
results in a macrofilaricidal effect in O. volvulus
[13,15,16].
Doxycycline affects several stages in the parasite life
cycle. Embryonic stages from morulae to coiled Mf are
the most sensitive to Wolbachia depletion [13,15,16].
The development from L3 (infective larval stage) into
adult worms is also affected [17-20]. In the mammalian
host, Mf are apparently unaffected by the decreased
endobacterial load [12,17]. However, the effect of Wol-
bachia-depletion on O. volvulus larval development
from Mf to L3 in the obligate arthropod vector remains
unknown. Arumugam et al. showed that larvae of the
rodent filaria Litomosoides sigmodontis were dependent
upon the endosymbionts for development into infective
L3 larvae in the mite vector [17]. Fewer female worms
were able to develop from Wolbachia depleted Mf,
because of their need of a higher threshold level of
endobacteria to survive.
This study was designed to investigate whether Wol-
bachia endobacteria are essential for the transmission of
onchocerciasis. To determine this, we analysed the role
of Wolbachia in the development of O. volvulus Mf into
L3 infective larvae in the Simulium vector by depleting
the endobacteria from the Mf prior to their ingestion by
blackflies during a blood meal.
Methods
Ethical approval
This study received ethical clearance from the Institu-
tional Review Board of the Tropical Medicine Research
Station, Kumba and was conducted in accordance with
the Helsinki Declaration of 1975 as revised in 1983,
2000 and 2002.
Selection of study patients and treatment
In November and December 2006, participants for the
study were recruited in four neighbouring villages in an
onchocerciasis-endemic region of South West Camer-
oon (Figure 1). Patients for the study were selected from
male volunteers, aged 21 to 50 years, after informed
consent was signed. Exclusion criteria were abnormal
hepatic (SGPT and SGOT) and renal (creatinine)
functions, persons with chronic infections and under
prolonged medication, alcohol abuse and intolerance to
doxycycline. As there was mass treatment with ivermec-
tin in the area in April 2006, all patients were asked
whether they took their doses at this time or any time
before, but all volunteers answered in the negative.
Inclusion criteria were absence of other clinically mani-
fested diseases as assessed by a medical doctor and ≥ 10
Mf in skin biopsies. Two bloodless skin biopsies, one
from each iliac crest of each participant, were aseptically
obtained using a Holth corneoscleral punch. Each biopsy
w a si m m e r s e di n2d r o p so f0 . 9 %N a C ls o l u t i o ni na
separate well of a labelled 96-well round-bottom micro-
titer plate. The plates were transported to the laboratory
and skin biopsies were incubated overnight at room
temperature to allow the emergence of Mf into the sal-
ine solution. The Mf were counted using 10-fold magni-
fication of a microscope and the number of Mf were
expressed as Mf per skin biopsy.
Twelve volunteers were blindly allocated into two
treatment groups. One group of 7 volunteers received
doxycycline (200 mg/day) for 6 weeks while the second
group of 5 volunteers received matching placebo.
Infection of wild Simulium flies with Onchocerca volvulus
Before and after treatment, the volunteers were brought
to a pre-selected O. volvulus-free capture point near a
Simulium breeding site on the bank of the River Mungo
to allow Simulium damnosum flies, the vector of O. vol-
vulus, to take a blood meal. The site was chosen based
on the results of dissection of wild Simulium flies to
determine the natural parous, infection and infective
rates, the latter two variables indicating that there was
no O. volvulus e n d e m i ct ot h ec a p t u r es i t e( T a b l e1 ) .
These parameters were monitored throughout the study
period. The fed flies were captured on the volunteers in
small plastic containers. Containers for each volunteer
were kept separately in plastic baskets. At least four
hundred flies were caught from each patient in four
days at each time point. Transport to the insectarium
was carried out in cold boxes. The flies were then kept
for 7 days at 25°C and 80% relative humidity to allow
the Mf to develop into infective third stage larvae (L3).
Larvae were isolated from the flies by dissection using
a dissecting microscope and their developmental stages
were scored. The number of flies dissected at each time
point varied due to different fly mortality rates. The iso-
lated developmental stages of the larvae (L1, L2 and L3)
were stored separately in 80% ethanol. At least two
tubes each containing different numbers of L1, L2 and
L3 isolated from flies fed on each volunteer at each time
point were stored for later DNA extraction and quantifi-
cation of Wolbachia.
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treatment
During the following 5 months post-treatment, flies
were captured on a monthly basis on the volunteers as
described above (Figure 1). Skin biopsies were also
obtained from the patients at each time point to assess
their Mf load after the antibiotic treatment. After count-
ing, the Mf were also stored in 80% ethanol for later
quantitative PCR analysis to determine their Wolbachia
content.
Kinetics of larval development after anti-wolbachial
therapy
The total number of L1 (first larval stage), L2 (second lar-
val stage) and L3 (third, infective larval stage) collected
after dissection of the flies was calculated for doxycycline
and placebo treated individuals. The proportion of each
larval stage generated for that month in each group was
calculated and plotted against the month of dissection to
follow the kinetics of the development of larvae in both
treatment groups. At pre-treatment and one month fol-
low-up, the L1 and L2 larvae counts were combined.
DNA extraction from larvae
One tube each of the different stages of larvae (L1, L2
and L3) per time point preserved in ethanol was
randomly selected for DNA extraction and quantifica-
tion of Wolbachia. The larvae preserved in ethanol were
first centrifuged at 1800 rpm (Multifuge 4KR, LH4000-
75006475, Heraeus, Haunau, Germany) for five minutes.
The ethanol was slowly removed with a pipette without
disturbing the larvae, leaving 100 μlo fv o l u m e .T h e s e
larvae were then suspendedi nt h er e m a i n i n ge t h a n o l
and transferred to a new tube.
DNA was extracted using the QIAamp
® DNA mini
Kit (Qiagen, Hilden, Germany) following the tissue pro-
tocol of the kit with the following modifications to
achieve the maximum amount of quality DNA. The
incubation period with proteinase K (Qiagen) was
extended from 10 min to overnight at 56°C. Wash buf-
fers 1 and 2 were increased to 700 μlf o l l o w e db ye l u -
tion with 2×50 μl of AE buffer. For each elution step,
the columns were incubated with AE buffer for 5 min-
utes at room temperature prior to centrifugation.
Quantitative real-time PCR
To determine the amount of Wolbachia in the larvae
isolated from the vector captured after having fed on
doxycycline or placebo treated individuals, the purified
DNA samples of randomly selected larvae for each
volunteer and time point were analysed by quantitative
real-time PCR. Primers and hybridisation probe were
Figure 1 Study timeline of recruitment, treatment and analysis. Patients were recruited in November/December 2006. After the informed
consent was signed by each volunteer, skin biopsies were taken from which Mf were isolated and counted. Volunteers were allocated into two
treatment groups. Before treatment with doxycycline or placebo (pre-treatment, month 0), volunteers were brought to the capture side to allow
Simulium damnosum flies to take a blood meal. Flies were captured and raised in an insectarium for seven days. After dissecting the flies
Onchocerca volvulus larvae were counted. This was repeated monthly for five months after doxycycline treatment was completed.
Table 1 Endemicity of Onchocerca volvulus infection in Simulium damnosum flies, Mungo river Etam, Cameroon
Date Flies captured Flies dissected Parous (%) Nulliparous (%) Infected (%) Infective (%)
June 2006 702 702 256
(36.5)
446
(63.5)
2
(0.78)
0
(0.0)
July 2006 483 483 46
(9.5)
437
(90.5)
0
(0.0)
0
(0.0)
September 2006 537 537 36
(6.7)
501
(93.3)
0
(0.0)
0
(0.0)
Total 1722 1722 338
(19.6)
1384
(80.4)
2
(0.59)
0
(0.0)
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Wolbachia ftsZ gene (GenBank accession No.
AJ276501), which codes for a single-copy cell division
protein. For all samples, the following master mix was
used: 1 × QuantiTect
® Virus NR Master Mix (Qiagen),
300 nM each forward and reverse primers (Table 2), 50
nM TaqMan hybridisation probe with the fluorescent
dye 6-FAM (6-carboxyfluorescein) and Tamra (Biomers,
Ulm, Germany) and 10 μlo fs a m p l eD N Ai na2 0μl
reaction. The PCR program utilised a two-step reaction
of the following conditions in a Rotor Gene 6000 (Cor-
bett Research, Sydney, Australia): 1 × 5 min at 95°C, 45
cycles of 94°C for 10s and 58°C for 45s. Fluorescence
was acquired on the FAM channel at 58°C. A second
PCR was performed to quantify O. volvulus b-actin
(GenBank accession no. M84916) to normalise the ftsZ
values [22]. The optimised PCR conditions were: 1 ×
HotStar
® Taq Polymerase buffer (Qiagen), 4 mM
MgCl2, 200 μMd N T P ,3 0 0n Me a c hf o r w a r da n d
reverse primers (Table 2), 0.2 μl of Sybr Green (1:1,000
diluted in DMSO, Roche, Mannheim, Germany), 2.5 U
HotStar
® Taq Polymerase and 2 μl DNA in a 20 μl reac-
tion. The PCR profile used a 3-step program with an
initial 95°C for 15 min, followed by 35 cycles at 94°C for
10s, 52°C for 15s and finally 72°C for 15s. Fluorescence
was acquired on the FAM channel at the end of the
extension step.
In both PCR assays, each sample was analysed in tri-
plicate. Every run contained a plasmid containing
sequences specific for Wolbachia ftsZ or O. volvulus
actin genes with a known number of copies for use as a
standard. A no-template control of water instead of
sample DNA was used as negative control. Copy num-
bers for each gene were calculated using a modification
of the comparative quantification formula as described
previously [23]. Using the Rotor Gene 6000 version 6.0
software the amplification (A) of each sample was calcu-
lated and the mean taken from replicate samples (sam).
A plasmid containing either the ftsZ or b-actin sequence
was quantified and copies/μl determined for use as a
reference (ref) in each PCR run. The amplification factor
of the sample compared to the specific reference was
then calculated using the following formula: Aref^take
offref/Asam^take offsam. The take off is defined as the
crossing point cycle where all measured samples are
20% above background. The amplification factor was
then multiplied by the known concentration of the
reference to give copies/μl. The ftsZ/b-actin ratio was
then calculated.
To exclude inhibition of the PCR reaction by inhibi-
tors in the DNA a third PCR with a plasmid containing
a fragment of the murine Interferon-g gene was per-
formed in the presence of the extracted DNA. The sam-
ples were set up for real-time PCR with a master mix
containing 1 × HotStar
® Taq Polymerase buffer (Qia-
gen), 200 μm dNTP, 400 nM each of forward and
reverse primer (Table 2), 0.2 μlS Y B R
® Green (1:1000
diluted in DMSO, Roche, Mannheim, Germany), 2.5
units HotStar
® Taq Polymerase, 2 μl reference Plasmid
DNA and 2 μls a m p l eD N Ai na2 0μl reaction. The
PCR profile was: 1 × 15 min at 95°C, 45 cycles of 94°C
for 15s, 58°C for 20s, 72°C for 20s. Fluorescence was
acquired on the FAM channel. An increase in cycle
number of ≥ 1 cycle over the plasmid-only sample indi-
cated the presence of PCR inhibitors in the DNA
extracted from the larvae.
Data analysis and statistics used
To test the interaction of treatment and time, we calcu-
lated the difference between follow-up time-points and
pre-treatment regarding the percentages of L3-larvae to
account for the development between pre-treatment and
after treatment in each patient. A repeated measures
ANOVA was then performed using PASW 18 (IBM,
Chicago, USA). The proportions of different larval stages
were analysed by calculating the L3/total larvae and L1
+L2/total larvae ratios. Statistical significance between
larvae from vectors fed on doxycycline or placebo trea-
ted individuals was determined with the Mann Whitney
Ut e s t( P≤ 0.05 was considered significant) using
PASW 18. Results were presented using the median.
Larval recoveries were expressed as median with 10-90
th
percentiles. Wolbachia quantities determined by PCR
were expressed as the ratio of ftsZ/b-actin.
Results
Selection of Onchocerca volvulus-free Simulium capture
site
Before bringing O. volvulus infected volunteers to the
blackfly capture site, we determined the natural parous
and infection rates by collecting and dissecting wild
Simulium flies. A total of 1722 female flies were col-
lected in June, July and September of 2006. The flies
were dissected and O. volvulus infection status deter-
mined: 19.6% were parous (females are reproductively
mature) of which 2 (0.59%) were infected, but did not
Table 2 Primer and Probe sequences for quantification of
the Wolbachia ftsZ and Onchocerca volvulus b-actin genes
Gene target Name Sequence 5’-3’
O. volvulus Wol ftsZ Forward aggaatgggtggtggtactg
O. volvulus Wol ftsZ Reverse ctttaaccgcagctcttgct
O. volvulus Wol ftsZ Hybridization probe ccttgccgctttcgcaatcac
O. volvulus b-actin Forward gtgctacgttgctttggact
O. volvulus b-actin Reverse gtaatcacttggccatcagg
Murine Interferon g Forward tcaagtggcatagatgtggaagaa
Murine Interferon g Reverse tggctctgcaggattttcatg
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blackfly population was sexually mature, seeking blood
meals, and their river location was essentially free of
endogenous O. volvulus infections.
Kinetics of larval development
To determine the skin microfilarial loads and recovery
of O. volvulus larvae from flies that had fed on doxycy-
cline or placebo treated individuals, skin biopsies and
dissected flies were analysed for developing larvae. Mf
were counted and expressed as Mf per skin biopsy. The
median number of L1, L2, and L3 larvae collected after
fly dissection was calculated per treatment group (Table
3). Because the number of flies that were dissected from
each volunteer was different due to different numbers
recovered at the biting site and different survival rates
in the insectarium, the proportions of each larval stage
that developed in each treatment group were plotted
against the month of dissection (month post-treatment)
to follow the kinetics of larval development (Figure 2).
A repeated measures ANOVA determined that there
was a significant difference in L3 recovery between the
5 measurement time-points (P < 0.001, Pillai-Spur) but
no clear interaction between the measurement time-
points and the treatment (P = 0.092, Pillai-Spur),
although the doxycycline group was different (P =
0.005).
Since there was no clear interaction, pair-wise com-
parisons between the treatment groups at each time-
point were performed. Starting three months post-treat-
ment, differences in the median recovery of L1+L2 and
L3 from flies fed on the doxycycline treated volunteers
were seen. The proportions of L1+L2 larvae recovered
from flies that had fed on doxycycline treated
individuals were higher at 3, 4 and 5 months post- treat-
ment (Figure 2). At three and five months post-treat-
ment, the differences were significant compared to
placebo (P < 0.05, Mann-Whitney U test). Correspond-
ingly, beginning at three months post-treatment, a
decrease in the proportion of L3 that developed in flies
that had fed on doxycycline treated individuals as com-
pared to placebo treated individuals was observed, with
a significant difference seen for months 3 and 5 (P <
0.05, Mann-Whitney U test; Figure 2).
Wolbachia depletion after treatment with doxycycline
To analyse the effect of treatment with antibiotic on the
bacterial endosymbionts of O. volvulus Mf from the skin
and larvae isolated from the vector, a quantitative real-
time PCR assay was established for the O. volvulus Wol-
bachia ftsZ gene. The detection limit of the PCR was
increased to 30 ftsZ copies (1 ftsZ =1Wolbachia)c o m -
pared to our previous study [13]. For normalisation to
worm material in the individual sample, a second PCR
assay for O. volvulus b-actin was performed [22].
Compared to the placebo group, fewer samples were
positive for ftsZ above the PCR detection limit in the
Mf from doxycycline treated individuals at 2, 3, 4 and 5
months post-treatment. Analysis of the Mf from skin
biopsies showed a > 50% reduction in the number of
Wolbachia one month post-treatment in the doxycycline
treated group (Table 4). Wolbachia reduction further
increased to 81% in the follow-up time points. At the
two month follow-up only 2/6 Mf samples (33%) gave a
positive ftsZ signal in the PCR, and further decreased to
only 1/7 samples (14%) being ftsZ positive at the 5
month follow-up. A similar pattern was seen in all larval
stages collected from the vector. In contrast, in the
Table 3 Larval recoveries from skin snips and blood-fed black flies of doxycycline and placebo treated volunteers
Mf L1/L2 L3
Month
a Doxy
b
n=7
Placebo
n=5
Doxy
n=7
c
Placebo
n=5
Doxy
n=7
Placebo
n=5
02 6
d
(13-80)
25
(10-76)
52
(45-157)
124
(71-155)
703
(509-1214)
789
(396-941)
14 2
(32-148)
83
(31-221)
29
(3-178)
33
(7-69)
281
(150-607)
313
(226-516)
24 0
(8-92)
114
(15-192)
133
(28-524)
112
(42-294)
797
(211-1615)
666
(385-963)
31 3
(7-40)
27
(10-113)
678
(167-965)
390
(90-877)
709
(335-1070)
983
(487-1169)
49
(2-127)
63
(9-92)
397
(103-1218)
217
(118-625)
318
(71-593)
406
(247-542)
52 8
(4-83)
63
(4-105)
426
(201-1476)
575
(388-1128)
53
(17-320)
240
(116-504)
a Month after treatment (Group 0 is pre-treatment)
b Treatment with Doxycycline (200 mg/day) for 6 weeks
c At 2 months post treatment only 6/7 doxycycline treated volunteers attended the follow-up meeting
d Median (range)
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point produced a clear signal above the detection limit
for bacterial ftsZ. Only two placebo samples (L1 at pre-
treatment and L2 at month 2 post-treatment) did not
h a v eas i g n a la b o v et h eftsZ detection limit. These sam-
ples also gave a weak signal for actin (data not shown),
indicating a very low DNA content. For all samples, a
PCR test for inhibition did not show any inhibition by
the sample. The negative ftsZ samples therefore did not
result from inhibitory factors in the DNA.
Discussion
In previous studies much work has been done showing the
requirement of Wolbachia for oogenesis, embryogenesis
and adult worm survival in infections with the filarial para-
site O. volvulus [11,12]. Other studies have analysed the
effects of tetracycline on larval development in the mam-
malian host. Tetracycline administered concomitantly
with the start of infection with L. sigmodontis led to signif-
icant growth retardation in worms [24]. Oral treatment
with tetracycline inhibited Brugia pahangi and Brugia
malayi development from L3 to adult worms in Mongo-
lian gerbils [18-20,25].
Different to animal models, little is known in human
infection about the effects of antibiotic treatment of the
mammalian host on the larval development in the insect
vector. Therefore, the focus of this study was to analyse
whether Mf from O. volvulus infected patients who had
Figure 2 Depletion of Wolbachia from Onchocerca volvulus larvae reduces the number of larvae that develop into the infective stage
in the Simulium vector. The proportion of larvae at each stage was calculated by dividing the number of larvae (stage L1+L2; L3) by the total
larvae collected from the captured blackflies after they had fed on the doxycycline (n = 7) or placebo (n = 5) treated volunteers. The proportion
of L1+L2 larvae in flies that had fed on doxycycline treated individuals (black bars) was higher beginning at 3 months post-treatment compared
to placebo. The proportion of L3 larvae in flies that had fed on doxycycline treated volunteers (white bars) was lower than that in the placebo
volunteers at 3, 4 and 5 months post-treatment. Proportions are given as percentages of median larval recovery. 100% corresponded to the total
number of larvae recovered at each indicated time.
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absent Wolbachia levels, could still develop into the
infective third stage larvae (L3) in the Simulium vector.
Simulium flies were allowed to bite O. volvulus
infected volunteers, then captured, raised in an insectar-
ium and then dissected to count larvae that had devel-
oped. Prior to bringing the infected volunteers to the
capture site, wild Simulium flies were captured and dis-
sected to determine the natural parous, infection and
infective rates. The very low infection (0.59%) of the
wild Simulium flies minimised the chance of an already
infected fly feeding on the study volunteers (Table 1).
Our results show that Mf treated with doxycycline,
and therefore depleted of their Wolbachia, developed
into L3 at a considerably lower rate than Mf from pla-
cebo treated patients during the observation period.
This was most apparent as a decrease of L3 with a cor-
responding increase of L1 and L2 seen in the doxycy-
cline group at 3, 4 and 5 months post-treatment (Figure
2). Whether the few remaining L3 with low numbers of
Wolbachia might be able to establish an infection in
humans remains an open question that is technically
and ethically impossible to answer for O. volvulus
infections.
To support the requirement of Wolbachia during lar-
val development, the depletion of the endobacteria was
v e r i f i e db yaq u a n t i t a t i v eP C Ra s s a yf o rt h eWolbachia
ftsZ gene. The PCR results showed a clear reduction of
Wolbachia ftsZ in the Mf after one month of antibiotic
treatment (52% compared to placebo), with Mf from
fewer than 50% of volunteer samples even having
detectable ftsZ at 2, 3, 4 and 5 months post-treatment
(Table 4). In the few doxycycline treated larval samples
that had an ftsZ signal, there was a clear reduction of
the ftsZ/b-actin r a t i o .B e c a u s es om a n yo ft h et r e a t e d
samples were negative for ftsZ,t h es a m p l es i z ew a st o o
small for a statistical test.
In addition to the above described effect on larval
development in the insect vector, depletion of the Wol-
bachia from O. volvulus Mf could have two other bene-
ficial effects. One possible benefit is a reduced chance of
Wolbachia-depleted larvae establishing an infection.
This is supported by work with the L. sigmodontis mur-
ine model of filarial infections and results from the fact
that Wolbachia increase the number and degranulation
of mast cells at the site of infection, resulting in greater
vascular permeability [26]. This effect is linked to the
TLR-2 innate immune receptor, which recognizes and is
activated by Wolbachia molecules [27-29]. The second
possible benefit is the reduction in pathology in already
infected individuals. Mf are the primary inducers of
pathology due to their induction of a strong immune
response when they die [30]. Work with animal models
and natural animal Onchocerca infections have shown
the importance of Wolbachia in the nematodes for
attracting immune cells to t h es i t eo fi n f e c t i o na n d
more importantly, a reduction in the damage done to
the eye when the endobacteria are depleted [30-33].
Changes in the number of L3 that developed from
Wolbachia-depleted Mf did not appear until 3 months
post treatment. We hypothesize that whatever products
that the endobacteria provided to the nematodes for
proper development are stable for two months and had
already been produced and made available to the Mf
prior to the depletion of the Wolbachia. When these Mf
are taken up by the vector, they are then able to con-
tinue their development until the endobacterial sub-
stances are depleted. A better understanding of this
Table 4 Effect of doxycycline and placebo treatment on Wolbachia loads in larval worms: results quantitative PCR
Mf (skin) L1 (vector) L2 (vector) L3 (vector)
Month
a Doxy
b Placebo Doxy Placebo Doxy Placebo Doxy Placebo
0 7/7
c
(0.06)
d
5/5
(0.02)
7/7
(0.058)
4/5
(0.03)
ee 6/6
(0.026)
5/5
(0.05)
1 6/7
(0.024)
4/4
(0.05)
4/7
(0.002)
5/5
(0.06)
ee 3/7
(0.008)
5/5
(0.03)
2 2/6
(0.068)
5/5
(0.22)
0/6 5/5
(0.11)
1/6
(0.007)
4/5
(0.06)
2/6
(0.011)
5/5
(0.05)
3 2/7
(0.085)
4/4
(0.70)
2/7
(0.06)
5/5
(0.41)
4/7
(0.029)
5/5
(0.16)
4/7
(0.059)
5/5
(0.19)
4 3/7
(0.085)
5/5
(0.30)
0/7 4/4
(0.32)
3/7
(0.002)
4/4
(0.16)
2/7
(0.036)
5/5
(0.43)
5 1/7
(0.167)
5/5
(0.56)
3/7
(0.001)
3/3
(0.08)
1/7
(0.002)
4/4
(0.09)
3/6
(0.017)
5/5
(0.12)
a Month after treatment
b Treatment with Doxycycline (200 mg/day) for 6 weeks
c Number of Wolbachia ftsZ positive volunteers
d Median ftsZ/b-actin ratio
e L1 and L2 counts were combined at months 0 and 1 of the study
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requirement of Wolbachia by filarial nematodes is
elucidated.
Although not significant, within the placebo group the
number of L3 larvae recovered from the Simulium
decreased over time post-treatment. This could be due
to the fall in temperatures (from 28°C to 24°C) in the
area at these time points reducing the capacity of the
Simuliae to support the infective L3 [34,35]. However,
this has to be confirmed in other experiments. The
results of a repeated measures ANOVA allowed us to
conclude that there was no interaction between the time
of measurement and treatment. Nevertheless, there is a
significant difference in the L3 reduction observed
between the doxycycline and the placebo treated volun-
teers (Figure 2).
Inhibition of larval development after antibiotic treat-
ment has been observed in several other studies. In a mur-
ine model with L. sigmodontis, significantly fewer L3
developed in the intermediate host if Mf were depleted of
their Wolbachia endobacteria with tetracycline treatment
[17]. Furthermore, infection of jirds with Wolbachia-
depleted L3 resulted in the development of very few
female worms, while male worm numbers were
unchanged. The few female worms that were able to
develop from Wolbachia-depleted Mf had endobacteria
levels equivalent to control worms indicating that these
worms developed from Mf with a Wolbachia threshold
needed for successful development of the larvae. Thus, the
O. volvulus L3 that had successfully developed at 4 and 5
months post treatment developed from Mf with the mini-
mum of Wolbachia endosymbionts to develop into L3.
In our study the larvae were not exposed to doxycy-
cline within the insect vector. The treatment occurred
before the blackflies had fed on the infected volunteers.
Because doxycycline rapidly blocks embryogenesis by
Wolbachia depletion [12], the Mf taken up by the flies
during the blood meal could only be those present at
the time of doxycycline treatment. Therefore we con-
cluded that Wolbachia depletion alone causes the
impairment of larval devel o p m e n ta n di sn o tad i r e c t
effect of the antibiotic on the larvae.
As noted, issues of small sa m p l es i z ea r o s ed u r i n g
some of our analyses. Although a clear difference in the
number of L3 that developed between the doxycycline
and placebo groups could be seen 4 months post-treat-
ment, the difference was not significant (P = 0.088).
Because there was a significant difference seen for this
parameter at 3 and 5 months, we are confident that
with a larger cohort of volunteers the difference seen at
4 months post-treatment would reach significance. Such
a larger study should also take into account the drop in
L3 development from pre-treatment to five months
post-treatment in the placebo group and be planned
during a season or an area where the ambient tempera-
ture does not differ by 4°C. A larger sample size would
also allow us to perform statistics on the quantitative
PCR results. We would like to note that the statistics
would only strengthen what we have already seen, i.e.
larvae which developed from Wolbachia-depleted Mf
did not have any or had very low levels of Wolbachia as
detected by quantitative real-time PCR.
Conclusions
To our knowledge, this is the first study analysing the
effects of antibiotic treatment of O. volvulus infected
humans on larval development in the insect vector.
These findings have epidemiological implications. The
results clearly show that depletion of Wolbachia not
only affects the larval stages and adult worms in the
mammalian host, it also has negative effects on larval
development in blackflies. The decrease in L3 produc-
tion, even though it is not 100%, could reduce the trans-
mission potential of blackflies following treatment of
communities with doxycycline to control onchocerciasis.
Thus anti-wolbachial therapy for filarial infections
would have an additive effect of interrupting transmis-
sion by 1) blocking embryogenesis, 2) macrofilaricidal
activity and 3) reduction of the number of L3 that can
be transmitted by blackflies that have fed on infected
persons before the Mf have been cleared from the skin.
A recent report on community-directed delivery of
doxycycline for the treatment of onchocerciasis indi-
cated that the delivery of doxycycline for six weeks is
achievable. The therapeutic coverage and the compli-
ance treatment rate achieved in this study coupled to
the known efficiency of doxycycline demonstrate that
mass administration may be used in selected problem
areas such as in areas co-endemic for loiasis to control
onchocerciasis [36].
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